Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Meta-Analysis of Study Data Finds 39% Overall Response Rate with Velcade Retreatment: Takeda
December 12, 2012
- Hisamitsu, Asahi Kasei Pharma to Comarket OAB Transdermal Drug
December 11, 2012
- Mochida Revving Up Collaboration Efforts in Biosimilars
December 11, 2012
- Otsuka Pharmaceutical Factory to Establish Infusion Products Subsidiary in India
December 11, 2012
- Ethical Drug Sales Up 6.1% in October: Crecon Report
December 11, 2012
- Feburic’s Market Share to Exceed 50% in Near Future: Teijin President Ohyagi
December 11, 2012
- Mylan Applies for Ciclosporin for Additional Indication Based on Data from Public Domain
December 11, 2012
- Teva Pharma Halts Sales of Pinatos Due to GMP Non-Compliance of South Korean Supplier
December 10, 2012
- JT Submits NDA for Anti-HIV Combination Drug, 1st NDA for Compound It Discovered
December 10, 2012
- US FDA Accepts NDA for Tacrolimus Extended-Release Capsules: Astellas
December 10, 2012
- Actavis Eyes 3 Monoclonal Antibodies for Entry into Japanese Biosimilar Market: EVP
December 10, 2012
- IP High Court Reverses JPO Ruling on Lipitor Patent
December 7, 2012
- With Spiriva Combination Product in PIII, BI Not Fear Competition in COPD Market: Chairman Barner
December 7, 2012
- Ex-JPMA Secretary General Expresses Hope for Globalization of Domestic Pharma Industry: JPLA Seminar
December 7, 2012
- ARB Market Nearing Its Limit; No More Growth in the Second Half?
December 7, 2012
- MSD Submits NDA for Novel Insomnia Treatment Suvorexant
December 6, 2012
- Lantus Shows Low Incidence of Hypoglycemia in Combination Use with OHA: Sanofi
December 5, 2012
- Astellas Initiates Patient Enrollment in PII Trial of Tivozanib for Triple Negative Breast Cancer
December 5, 2012
- US Merck Initiates Multinational PII/III Study for BACE Inhibitor for Alzheimer’s Disease
December 5, 2012
- Pediatric NDA for AcipHex Granted Priority Review by US FDA: Eisai
December 4, 2012
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…